HUTCHMED (China) (HMDCF) Curent Deferred Tax Liability (2015 - 2016)
HUTCHMED (China)'s (HMDCF) quarterly Curent Deferred Tax Liability came in at $1.4 million in Q4 2016, up 342.86% year-over-year from $308000.0 in Q1 2016, and up 342.86% quarter-over-quarter from $308000.0 in Q4 2015.
Powered by 
Analysis
HUTCHMED (China) (HMDCF) Curent Deferred Tax Liability (2015 - 2016) Analysis & Trends
HUTCHMED (China) (HMDCF) has reported Curent Deferred Tax Liability for 2 consecutive years, with $1.4 million the latest figure, recorded in Q4 2016.
- On a quarterly basis, Curent Deferred Tax Liability rose 342.86% year-over-year to $1.4 million in Q4 2016; TTM through Dec 2016 was $1.4 million, a 342.86% increase from a year earlier, with the FY2016 full-year figure at $1.4 million, up 342.86% from the prior year.
- Curent Deferred Tax Liability was $1.4 million for Q4 2016 at HUTCHMED (China), up from $308000.0 in the prior quarter.
- Over five years, Curent Deferred Tax Liability peaked at $1.4 million in Q4 2016 and troughed at $308000.0 in Q4 2015.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Curent Deferred Tax Liability (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 211.50 Bn | 197.51 Bn | 7.24 Bn | - |
| 2 | Gilead Sciences | 181.29 Bn | 178.11 Bn | 6.22 Bn | - |
| 3 | Vertex Pharmaceuticals | 132.16 Bn | 124.30 Bn | 2.84 Bn | - |
| 4 | Regeneron Pharmaceuticals | 82.55 Bn | 74.56 Bn | 3.93 Bn | - |
| 5 | Argenx Se | 61.65 Bn | 56.47 Bn | 1.37 Bn | - |
| 6 | Moderna | 54.65 Bn | 49.52 Bn | 52.00 Mn | - |
| 7 | Alnylam Pharmaceuticals | 34.18 Bn | 30.87 Bn | 992.69 Mn | - |
| 8 | Biogen | 31.36 Bn | 30.07 Bn | 1.96 Bn | - |
| 9 | Roivant Sciences | 30.01 Bn | 30.01 Bn | 1.16 Mn | - |
| 10 | HUTCHMED (China) | 376.85 Mn | 391.04 Mn | - | - |